TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Hypoglycaemia Notification Device Hyposafe H02

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any study related activities~* Type 1 diabetes diagnosed at least five years prior to inclusion in the study~* Impaired awareness and/or history of at least one severe hypoglycaemia within the preceding year~Exclusion Criteria:~* Severe cardiac disease~* History of stroke or cerebral haemorrhage and any other structural cerebral disease~* Active cancer or cancer diagnosis within the past 5 years~* Uraemia defined as s-creatinine ≥ 3 times upper reference value~* Liver disease defined as s-ALAT ≥ 3 times upper reference interval~* Epilepsy~* Use of antiepileptic drugs for any indication~* Clinically important hearing impairment~* Use of active implantable medical device including pacemaker and ICD-unit and cochlear implant~* Use of following drugs: Chemotherapeutic drugs of any kind, Methotrexate, Third generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone, paliperidone, risperidone, sertindole, amisulpride, olanzapine)~* Contraindications to the local anaesthetic used during implantation~* Known or suspected abuse of alcohol or any other neuro-active substances~* Infection at the site of device implantation~* Any haemorrhagic disease~* Females of childbearing potential who are pregnant or intend to become pregnant or are not using adequate contraceptive methods throughout the study~* Performing extreme sport, including scuba diving (snorkel diving is allowed) or parachute jumping~* Incapable of understanding the subject information or unlikely to complete the study for any reason~* Operating MRI scanners~* Operating handheld transceivers for communication (e.g. within the police, medical, fire, air traffic control, marine or military)~* Working at broadcast stations for television or FM/DAB radio~* Use of CGM or FGM with visible glucose measurements and activated glucose notifications~* Involved in therapies with medical devices that deliver electrical energy into the area around the implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- hyposafe H02 (Type: EXPERIMENTAL): All subjects included are assigned to hyposafe H02-testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients who have recently been hospitalized for heart failure~* live at home~* are receiving guideline recommended pharmacologic therapy~* do not regularly exercise (10 minutes or more a day of exercise most days of the week for the past week).~Exclusion Criteria:~* Patients, who have undertaken cardiac rehab within the 12 months prior to enrollment~* Cognitive or other impairment which prevents accurate application of intervention or inability to provide informed consent~* End Stage Renal Disease or receiving mechanical ventilation~* Receiving non-approved FDA-investigational agents or devices,~* Has received a heart transplant, a destination Ventricular Assist Device (LVAD), pacemaker, or implantable cardiac device~* previously used NMES (Neuromuscular electrical stimulation) or TENS (Transcutaneous electrical nerve stimulation)~* Uncontrolled arrhythmia's or 3 degree AV heart block~* are unable to correctly apply and operate the device even after instruction~* Those with wounds over area of proper placement of electrodes~* Those who are unable to speak and write English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neuromusclar electrical stimulation (Type: ACTIVE_COMPARATOR): NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time.
- Transcutaneous electrical stimulation (Type: SHAM_COMPARATOR): For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of a Low-Carbohydrate Diet to Improve Maternal Health After Childbirth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Delivery at University of Texas Medical Branch~* Body max index greater than or equal to 30 kilograms/meters squared at the final prenatal visit prior to delivery.~* Singleton gestation.~* Accessibility to the internet.~* Basic understanding and comprehension of the English language to be assessed by study personnel at the time of recruitment.~Exclusion Criteria:~* Diabetes mellitus on medication.~* Serious medical condition, such as heart failure, kidney failure, or severe asthma, as determined by the principle investigator.~* Planned pregnancy during study period.~* Enrolled in another trial that may affect outcome.~* Subject unlikely to be followed up after delivery.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): Subjects will receive standard counseling on obesity as part of routine postpartum care.
- Low carbohydrate diet education (Type: ACTIVE_COMPARATOR): Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
- Low carbohydrate diet education with behavioral component (Type: ACTIVE_COMPARATOR): Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male \& Females aged 65 and older~* Patients must meet the criteria for chronic idiopathic constipation for at least 12 weeks~* Patients must have had a colonoscopy within the past 5 years~* Patients must pass a balloon expulsion test at screening~* Patients must be able to comply and understand the use of a diary~Exclusion Criteria:~* Patients with a clinically significant medical condition that would interfere with the patient completing the trial~* Patients with loose stools at least once per week~* Patients with IBS~* Known allergies to the same class of drug and/or allergies to eggs~* Patients who require the use of manual maneuvers to have a bowel movement~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Melphalan With BBBD in Treating Patients With Brain Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Signed written informed consent form in accordance with institutional guidelines~* Histologically confirmed primary or metastatic CNS malignancy (Patients with metastatic disease must have histological confirmation of the primary cancer AND confirmation by surgical specimen, cerebrospinal fluid cytology, elevated tumor markers, or clinical evidence of CNS involvement)~* Single or multiple cerebellar or cerebral cortex lesions allowed~* Life expectancy at least 60 days~* Radiographically evaluable disease by MRI or CT scan~* Age 18 years or older~* At least 28 days since prior radiotherapy (systemic, cranial, and/or spinal)~* At least 28 days since prior chemotherapy (42 days for nitrosoureas)~* Adequate cardiac and pulmonary function to tolerate general anesthesia~* Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2~* Other tumor masses in the spinal cord allowed provided there is no radiographic or clinical evidence of spinal cord block~* Available for follow-up for at least one year following completion of treatment~* Fertile patients must use effective contraception for 2 months prior to, during, and for 3 months after study participation~* Pre-treatment lab tests within 14 days prior to initiation of treatment:~  * White blood cell count (WBC) \> 2,500/mm\^3~ * Absolute granulocyte count \> 1,200/mm\^3~ * Platelet count \> 100,000/mm\^3~ * Hematocrit \> 30% (transfusion allowed)~ * Bilirubin ≤ 2 times upper limit of normal (ULN)~ * Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times ULN~ * Creatinine ≤ 2 times ULN~* Subjects with history of smoking or emphysema require diffusing capacity of lung for carbon monoxide (DLCO) ≥ 80% of predicted value for age~* Histological sections submitted for pathology review~EXCLUSION CRITERIA:~* Radiographic evidence of excessive intra-cranial mass effect and/or spinal block~* Known hypersensitivity or intolerance to melphalan~* NCI CTC Grade 3 or greater baseline neurologic symptoms~* Immunologically compromised (Concurrent corticosteroids for tumor edema allowed)~* Unable to tolerate general anesthesia~* Pregnant, positive human chorionic gonadotropin (HCG) test, or lactating~* HIV positive~* Receiving concurrent radiotherapy or immunotherapy~* Serious illness that would preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability or legally authorized representative (LAR) to provide informed consent~2. Adult who has not had surgery within 10 days, admitted to the Sentara Norfolk General Hospital ICU Medical Teaching Services for any reason.~Exclusion Criteria:~1. Active or suspected bleeding~2. Platelet count less than 100,000 per microliter (mm3) of blood~3. Thrombolytic or anticoagulant treatment (including any doses of prophylactic UFH, LMWH or fondaparinux) during the current hospitalization~4. Initial estimated CLcr \< 30 ml/min as determined by the Cockcroft-Gault equation~5. Initial labs indicative or suggestive of rapidly rising serum Creatinine (\>1 mg/dL/day)~6. Pregnancy (for medicolegal considerations)~7. Patients with or expecting to require an epidural catheter~8. Patients who are expected to have an immediate (within 24h) need for surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): Fondaparinux treatment - one standard of care option
- 2 (Type: ACTIVE_COMPARATOR): Enoxaparin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~• Patients age 3 - 17 undergoing adenotonsillectomy~Exclusion Criteria:~* Down syndrome~* History of coagulopathy~* Craniofacial abnormalities other than plagiocephaly or submucous cleft palate (SMCP)~* Caregivers who cannot speak, read, or write in English proficiently~* Patients who take opioids during the enrollment period~* Patients who take chronic opioids~* Pregnancy~* Allergy to or contraindication for taking any of the study medications~* Patients who have the inability to communicate~* Patients who have the inability to localize pain

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Opioid pain control (Type: EXPERIMENTAL): Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Families will receive an opioid disposal education document.
- Opioid pain control + Disposal Pouch (Type: EXPERIMENTAL): Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Half of the families randomized to the opioid group will be further randomized to receive an opioid disposal bag + an opioid disposal education document. The pouch is a drug deactivation disposal pouch to dispose the opioid at home.
- Non-opioid pain control (Type: ACTIVE_COMPARATOR): Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary or by email/mail if no appointment was scheduled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Income Supplements On 30-Day Readmissions For Vulnerable Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A participant in the underlying enhanced care planning program~* aged 55 years or older~* attending an outpatient clinic appointment as part of the underlying enhanced care planning program within 10 days of being discharged from an inpatient hospital stay~* able to understand the study consent form (with interpretation services if needed)~Exclusion Criteria:~* The candidate is not discharged from the index admission to a community setting (e.g., they will be excluded if they are discharged to a skilled nursing facility)~* The candidate has a legal guardian with control over financial decision-making~* The candidate has been approached about the study during a previous encounter~* The index hospitalization was a planned admission

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Enhanced care planning only (plus $15 as compensation for participation)
- Intervention (Type: EXPERIMENTAL): Enhanced care planning plus a one-time $300 post-discharge income supplement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperekplexia~* GLRA1~* GLRB~* SCLA5~* GPHN~* Gephyrin~* ARHGEF9~Exclusion Criteria~* Age below 7 years~* Pregnancy~* Breast feeding~* Ongoing medication~* Cognitive impairment

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 year old male and female patients~2. All patients are referred for elective cardiac catheterization based on clinical indication~3. Cath shows mild or moderate (\<70% stenosis) CAD that does not require mechanical intervention~Exclusion Criteria:~1. Severe stenosis requires intervention.~2. Significant left main coronary artery disease (\>40%).~3. Acute MI or acute coronary syndrome with enzyme elevation or ischemic EKG changes~4. Patients with severe left ventricular dysfunction (EF\<35%)~5. Prior history of myocardial infarction~6. History of stroke within 3 months.~7. Recent history of thrombolytic~8. History of coronary intervention within previous 6 months.~9. Patients with history of coronary spasm~10. Patients with congestive heart failure (class III and IV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bradykinin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 12 years or older~* Blood culture positive for S. aureus~* At least two signs or symptoms attributable to S. aureus BSI/IE~* Known or suspected complicated S. aureus BSI and/or right-sided IE based on Modified Duke Criteria~* Not pregnant or breastfeeding and not of reproductive potential or agrees to remain abstinent or use contraception if of reproductive potential~Exclusion Criteria:~* Previously received exebacase~* Known or suspected left-sided IE~* Treatment with effective systemic anti-staphylococcal antibiotic for more than 72 hours within 7 days before randomization~* Presence of prosthetic valve or cardiac valve support ring, or presence of known or suspected infected hardware (orthopedic), prosthetic joint, or cardiac device~* Known polymicrobial BSI, or known ongoing systemic infection caused by other bacterial and/or fungal pathogen(s), and/or known to have coronavirus disease 2019 (COVID-19)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exebacase (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy